Metastatic Colorectal Cancer - Pipeline Review, H1 2013


#164358

338pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Metastatic Colorectal Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Colorectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Colorectal Cancer. 

Metastatic Colorectal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Colorectal Cancer.
  • A review of the Metastatic Colorectal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Colorectal Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Colorectal Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Colorectal Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Metastatic Colorectal Cancer Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Metastatic Colorectal Cancer 11
Metastatic Colorectal Cancer Therapeutics under Development by Companies 13
Metastatic Colorectal Cancer Therapeutics under Investigation by Universities/Institutes 18
Late Stage Products 21
Comparative Analysis 21
Mid Clinical Stage Products 22
Comparative Analysis 22
Early Clinical Stage Products 23
Comparative Analysis 23
Discovery and Pre-Clinical Stage Products 24
Comparative Analysis 24
Metastatic Colorectal Cancer Therapeutics - Products under Development by Companies 25
Metastatic Colorectal Cancer Therapeutics - Products under Investigation by Universities/Institutes 31
Companies Involved in Metastatic Colorectal Cancer Therapeutics Development 34
Bristol-Myers Squibb Company 34
Boehringer Ingelheim GmbH 35
F. Hoffmann-La Roche Ltd. 36
Kyowa Hakko Kirin Co., Ltd. 37
Amgen Inc. 38
Sanofi-Aventis 39
AstraZeneca PLC 40
Eli Lilly and Company 41
Genentech, Inc. 42
Daiichi Sankyo Company, Ltd 43
Merck & Co., Inc. 44
Takeda Pharmaceutical Company Limited 45
Light Sciences Oncology, Inc. 46
Celltrion, Inc. 47
Novartis AG 48
Pfizer Inc. 49
Taiho Pharmaceutical Co., Ltd. 50
Cell Therapeutics, Inc. 51
Enzon Pharmaceuticals, Inc. 52
Bayer AG 53
Merck KGaA 54
Alchemia Limited 55
IMMUNOMEDICS, INC 56
Oncolytics Biotech Inc. 57
Oncothyreon Inc 58
ARQULE, INC 59
Zenotech Laboratories Limited 60
Regeneron Pharmaceuticals, Inc. 61
Synta Pharmaceuticals Corp. 62
Morphotek, Inc. 63
INSYS Therapeutics, Inc. 64
Actinium Pharmaceuticals, Inc. 65
Celator Pharmaceuticals, Inc. 66
OncoMed Pharmaceuticals, Inc. 67
Merrimack Pharmaceuticals, Inc. 68
Jennerex Biotherapeutics, Inc. 69
MolMed S.p.A. 70
Globeimmune, Inc. 71
Biothera 72
AVEO Pharmaceuticals, Inc. 73
Cytavis Biopharma GmbH 74
Medical Enzymes AG 75
Therapure Biopharma Inc. 76
Oncozyme Pharma Inc. 77
Metastatic Colorectal Cancer - Therapeutics Assessment 78
Assessment by Monotherapy Products 78
Assessment by Combination Products 79
Assessment by Route of Administration 80
Assessment by Molecule Type 82
Drug Profiles 85
RG-7414 - Drug Profile 85
regorafenib - Drug Profile 86
DI-17-E-6 - Drug Profile 88
cixutumumab - Drug Profile 90
brostallicin - Drug Profile 91
onartuzumab - Drug Profile 93
selumetinib sulfate - Drug Profile 95
irinotecan hydrochloride - Drug Profile 97
Liposomal SN-38 - Drug Profile 99
everolimus - Drug Profile 101
ramucirumab - Drug Profile 104
ramucirumab - Drug Profile 108
pexastimogene devacirepvec - Drug Profile 112
ganetespib - Drug Profile 114
irinotecan hydrochloride - Drug Profile 117
MORAb-004 - Drug Profile 119
orantinib - Drug Profile 121
(tipiracil hydrochloride + trifluridine) - Drug Profile 123
panitumumab - Drug Profile 124
GlutaDON - Drug Profile 127
talaporfin sodium - Drug Profile 129
pentamidine isethionate - Drug Profile 131
TF-2 - Drug Profile 133
aviscumine - Drug Profile 135
demcizumab - Drug Profile 137
GI-4000 - Drug Profile 140
axitinib + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 142
everolimus + [bevacizumab] - Drug Profile 144
Irinotecan Hydrochloride + Floxuridine - Drug Profile 146
motesanib + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 148
motesanib + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] + [panitumumab] - Drug Profile 150
motesanib + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] + [panitumumab] - Drug Profile 152
cediranib maleate + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 154
conatumumab + [panitumumab] - Drug Profile 156
nintedanib + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 157
ganitumab + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 159
conatumumab + ganitumab + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin] - Drug Profile 161
NGR-hTNF + [capecitabine] + [oxaliplatin] - Drug Profile 163
afatinib - Drug Profile 165
BMS-540215 + Erbitux + Irinotecan - Drug Profile 167
pegdinetanib + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 168
KRN-330 + [irinotecan hydrochloride] - Drug Profile 170
EMD-525797 + [cetuximab] + [irinotecan hydrochloride] - Drug Profile 171
drozitumab + [bevacizumab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 173
vismodegib + [bevacizumab] + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 175
MSC1936369B + FOLFIRI - Drug Profile 177
tivantinib + [cetuximab] + [irinotecan hydrochloride] - Drug Profile 179
efatutazone + [fluorouraci] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 181
dalotuzumab - Drug Profile 182
imgatuzumab - Drug Profile 184
PGG beta-glucan + [cetuximab] - Drug Profile 186
firtecan pegol + [cetuximab] - Drug Profile 187
Xelox - Drug Profile 188
decitabine + [panitumumab] - Drug Profile 190
semaxanib + [fluorouracil] + [leucovorin] - Drug Profile 191
enzastaurin hydrochloride + [bevacizumab] + [fluorouracil] + [leucovorin] - Drug Profile 193
rilotumumab + [panitumumab] - Drug Profile 195
sorafenib tosylate + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 197
AUY-922 - Drug Profile 199
Reolysin + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 201
PGG beta-glucan + [cetuximab] + [irinotecan hydrochloride] - Drug Profile 203
sorafenib tosylate + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 205
trebananib + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 207
erlotinib hydrochloride + [bevacizumab] + [capecitabine] + [oxaliplatin] - Drug Profile 209
simvastatin + [cetuximab] - Drug Profile 211
RG-7597 - Drug Profile 212
sorafenib tosylate + [capecitabine] - Drug Profile 214
TS-1 + Irinotecan + Bevacizumab - Drug Profile 215
BKM-120 + [irinotecan hydrochloride] - Drug Profile 217
erlotinib hydrochloride + [bevacizumab] + [capecitabine] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 218
Capecitabine + Oxaliplatin + Cetuximab + Bevacizumab - Drug Profile 220
tigatuzumab + [fluorouracil] + [irinotecan] + [leucovorin calcium] - Drug Profile 222
Aflibercept + FOLFIRI - Drug Profile 224
Aflibercept + FOLFIRI - Drug Profile 226
PX-866 + [cetuximab] - Drug Profile 228
aflibercept - Drug Profile 229
cetuximab biosimilar - Drug Profile 231
bevacizumab biosimilar - Drug Profile 232
(tegafur + gimeracil + oteracil potassium) - Drug Profile 233
(tegafur + gimeracil + oteracil potassium) - Drug Profile 236
IMM-101 - Drug Profile 239
GI-4000 + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 241
RO-5083945 + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 243
conatumumab + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 245
FOLF(HA)Iri - Drug Profile 247
talaporfin sodium + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 249
talaporfin sodium + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 251
TBI-302 - Drug Profile 253
tivozanib + [everolimus] - Drug Profile 254
brivanib alaninate + [irinotecan hydrochloride] - Drug Profile 256
OCZ103-OS + [fluorouracil] + [irinotecan hydrochloride] + [leucovorin calcium] - Drug Profile 257
pexastimogene devacirepvec + [irinotecan hydrochloride] - Drug Profile 259
selumetinib sulfate + [irinotecan hydrochloride] - Drug Profile 261
onartuzumab + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 262
RG-7414 + [bevacizumab] + [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 264
OCZ103-OS+ [fluorouracil] + [leucovorin calcium] + [oxaliplatin] - Drug Profile 266
Dendritic Cell Vaccine - Drug Profile 268
Actimab-C - Drug Profile 269
BKM-120 + modified FOLFOX6 - Drug Profile 270
HLA-A24 Restricted Epitope Peptide Cocktail Vaccine - Drug Profile 271
LDE-225 + [buparlisib] - Drug Profile 272
Reolysin + FOLFOX-6 + Avastin - Drug Profile 273
aflibercept + [capecitabine] - Drug Profile 275
Leucovorin + Mitomycin C - Drug Profile 277
Metastatic Colorectal Cancer Therapeutics - Drug Profile Updates 278
Metastatic Colorectal Cancer Therapeutics - Discontinued Products 323
Metastatic Colorectal Cancer Therapeutics - Dormant Products 324

Appendix 330
Methodology 330
Coverage 330
Secondary Research 330
Primary Research 330
Expert Panel Validation 330
Contact Us 331
Disclaimer 331

Number of Products Under Development for Metastatic Colorectal Cancer, H1 2013 18
Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2013 19
Number of Products under Development by Companies, H1 2013 21
Number of Products under Development by Companies, H1 2013 (Contd..1) 22
Number of Products under Development by Companies, H1 2013 (Contd..2) 23
Number of Products under Development by Companies, H1 2013 (Contd..3) 24
Number of Products under Investigation by Universities/Institutes, H1 2013 26
Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 27
Comparative Analysis by Late Stage Development, H1 2013 28
Comparative Analysis by Mid Clinical Stage Development, H1 2013 29
Comparative Analysis by Early Clinical Stage Development, H1 2013 30
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013 31
Products under Development by Companies, H1 2013 32
Products under Development by Companies, H1 2013 (Contd..1) 33
Products under Development by Companies, H1 2013 (Contd..2) 34
Products under Development by Companies, H1 2013 (Contd..3) 35
Products under Development by Companies, H1 2013 (Contd..4) 36
Products under Development by Companies, H1 2013 (Contd..5) 37
Products under Investigation by Universities/Institutes, H1 2013 38
Products under Investigation by Universities/Institutes, H1 2013 (Contd..1) 39
Products under Investigation by Universities/Institutes, H1 2013 (Contd..2) 40
Bristol-Myers Squibb Company, H1 2013 41
Boehringer Ingelheim GmbH, H1 2013 42
F. Hoffmann-La Roche Ltd., H1 2013 43
Kyowa Hakko Kirin Co., Ltd., H1 2013 44
Amgen Inc., H1 2013 45
Sanofi-Aventis, H1 2013 46
AstraZeneca PLC, H1 2013 47
Eli Lilly and Company, H1 2013 48
Genentech, Inc., H1 2013 49
Daiichi Sankyo Company, Ltd, H1 2013 50
Merck & Co., Inc., H1 2013 51
Takeda Pharmaceutical Company Limited, H1 2013 52
Light Sciences Oncology, Inc., H1 2013 53
Celltrion, Inc., H1 2013 54
Novartis AG, H1 2013 55
Pfizer Inc., H1 2013 56
Taiho Pharmaceutical Co., Ltd., H1 2013 57
Cell Therapeutics, Inc., H1 2013 58
Enzon Pharmaceuticals, Inc., H1 2013 59
Bayer AG, H1 2013 60
Merck KGaA, H1 2013 61
Alchemia Limited, H1 2013 62
IMMUNOMEDICS, INC, H1 2013 63
Oncolytics Biotech Inc., H1 2013 64
Oncothyreon Inc, H1 2013 65
ARQULE, INC, H1 2013 66
Zenotech Laboratories Limited, H1 2013 67
Regeneron Pharmaceuticals, Inc., H1 2013 68
Synta Pharmaceuticals Corp., H1 2013 69
Morphotek, Inc., H1 2013 70
INSYS Therapeutics, Inc., H1 2013 71
Actinium Pharmaceuticals, Inc., H1 2013 72
Celator Pharmaceuticals, Inc., H1 2013 73
OncoMed Pharmaceuticals, Inc., H1 2013 74
Merrimack Pharmaceuticals, Inc., H1 2013 75
Jennerex Biotherapeutics, Inc., H1 2013 76
MolMed S.p.A., H1 2013 77
Globeimmune, Inc., H1 2013 78
Biothera, H1 2013 79
AVEO Pharmaceuticals, Inc., H1 2013 80
Cytavis Biopharma GmbH, H1 2013 81
Medical Enzymes AG, H1 2013 82
Therapure Biopharma Inc., H1 2013 83
Oncozyme Pharma Inc., H1 2013 84
Assessment by Monotherapy Products, H1 2013 85
Assessment by Combination Products, H1 2013 86
Assessment by Stage and Route of Administration, H1 2013 88
Assessment by Stage and Molecule Type, H1 2013 91
Metastatic Colorectal Cancer Therapeutics - Drug Profile Updates 285
Metastatic Colorectal Cancer Therapeutics - Discontinued Products 330
Metastatic Colorectal Cancer Therapeutics - Dormant Products 331
Metastatic Colorectal Cancer Therapeutics - Dormant Products (Contd..1) 332
Metastatic Colorectal Cancer Therapeutics - Dormant Products (Contd..2) 333
Metastatic Colorectal Cancer Therapeutics - Dormant Products (Contd..3) 334
Metastatic Colorectal Cancer Therapeutics - Dormant Products (Contd..4) 335
Metastatic Colorectal Cancer Therapeutics - Dormant Products (Contd..5) 336
Number of Products under Development for Metastatic Colorectal Cancer, H1 2013 18
Products under Development for Metastatic Colorectal Cancer - Comparative Analysis, H1 2013 19
Products under Development by Companies, H1 2013 20
Products under Investigation by Universities/Institutes, H1 2013 25
Late Stage Products, H1 2013 28
Mid Clinical Stage Products, H1 2013 29
Early Clinical Stage Products, H1 2013 30
Discovery and Pre-Clinical Stage Products, H1 2013 31
Assessment by Monotherapy Products, H1 2013 85
Assessment by Combination Products, H1 2013 86
Assessment by Route of Administration, H1 2013 87
Assessment by Stage and Route of Administration, H1 2013 88
Assessment by Molecule Type, H1 2013 89
Assessment by Stage and Molecule Type, H1 2013 90